List view / Grid view
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
30 September 2015 | By Victoria White
If approved, Translarna would be the first oral protein restoration treatment that targets the underlying cause of nonsense mutation cystic fibrosis...
21 September 2015 | By Roche
Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015...
7 July 2015 | By
Celtaxsys has gained clearance from the US FDA to begin a Phase 2 clinical trial of acebilustat in adult patients with cystic fibrosis (CF) in the US...
3 July 2015 | By Victoria White
The FDA has approved Vertex’s Orkambi, the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation...
3 July 2015 | By Victoria White
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial...
18 May 2015 | By Victoria White
Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published...
